Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
100th anniversary
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Substance Use Disorders (Upcoming)
Clonal Hematopoiesis (Upcoming)
Sex Differences in Medicine (Sep 2024)
Vascular Malformations (Apr 2024)
Lung inflammatory injury and tissue repair (Jul 2023)
Immune Environment in Glioblastoma (Feb 2023)
Korsmeyer Award 25th Anniversary Collection (Jan 2023)
View all review series ...
Viewpoint
Collections
In-Press Preview
Clinical Medicine
Research Letters
Letters to the Editor
Editorials
Commentaries
Reviews
Viewpoints
Top read articles
Clinical Medicine
H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~DeBakey Clinical Medical Research Award
Corinne L. Williams
Corinne L. Williams
Published September 10, 2019
Citation Information:
J Clin Invest.
2019;
129(10)
:3963-3965.
https://doi.org/10.1172/JCI132533
.
View:
Text
|
PDF
News
H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~DeBakey Clinical Medical Research Award
Text
PDF
Abstract
Authors
Corinne L. Williams
×
Figure 1
The recipients of the 2019 Lasker~DeBakey Clinical Medical Research Award.
Options:
View larger image
(or click on image)
Download as PowerPoint
H. Michael Shepard, Dennis Slamon, and Axel Ullrich are being recognized for their work toward the development of Herceptin, the first targeted-mAb therapy for cancer. Photo of Axel Ullrich courtesy of the Mary and Albert Lasker Foundation.